Orelabrutinib ( DrugBank: Orelabrutinib )

3 diseases

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05284175 (ClinicalTrials.gov)	April 2022	9/3/2022	A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder	A Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinib in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder	Neuromyelitis Optica Spectrum Disorder	Drug: Orelabrutinib	Peking Union Medical College Hospital	Beijing InnoCare Pharma Tech Co., Ltd.;GCP ClinPlus Co., Ltd.	Not yet recruiting	18 Years	75 Years	All	23	N/A	China
2	NCT04711148 (ClinicalTrials.gov)	March 1, 2021	8/1/2021	A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity	Relapsing Remitting Multiple Sclerosis	Other: placebo;Drug: orelabrutinib	Beijing InnoCare Pharma Tech Co., Ltd.	NULL	Recruiting	18 Years	55 Years	All	160	Phase 2	United States;China;Poland;Ukraine

臨床試験数 : 137 / 薬物数 : 127 - (DrugBank : 55) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 153

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100045594	2021-04-19	2021-04-19	A single center prospective clinical study of Orelabrutinib in the treatment of relapsed/refractory autoimmune hemolytic anemia/Evans syndrome	A single center prospective clinical study of Orelabrutinib in the treatment of recurrent refractory autoimmune hemolytic anemia/Evans syndrome	Relapsed/refractory autoimmune hemolytic anemia /Evans syndrome	Single arm:Orelabrutinib;	Tianjin Medical University General Hospital	NULL	Recruiting			Both	Single arm:20;	Phase 4	China

臨床試験数 : 363 / 薬物数 : 212 - (DrugBank : 43) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 138

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05232149 (ClinicalTrials.gov)	February 2022	20/12/2021	A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia	A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune Thrombocytopenia	Primary Immune Thrombocytopenia	Drug: Orelabrutinib( lower dose);Drug: Orelabrutinib( higher dose)	Beijing InnoCare Pharma Tech Co., Ltd.	NULL	Not yet recruiting	18 Years	80 Years	All	30	Phase 2	China
2	NCT05020288 (ClinicalTrials.gov)	September 1, 2021	12/8/2021	A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP	A Prospective, Open-label, Multicenter,Single-armed Study of Orelabrutinib in the Treatment of Refractory Primary Immune Thrombocytopenia (ITP)	Immune Thrombocytopenia;Bruton's Tyrosine Kinase	Drug: Orelabrutinib	Shandong University	NULL	Not yet recruiting	18 Years	70 Years	All	40	Phase 2	NULL